onfekafusp alfa

Home
Ligands
onfekafusp alfa

GtoPdb Ligand ID: 9757

Synonyms: Fibronum | L19TNF-alpha

Comment: Onfekafusp alfa (Fibromun; L19-TNF) is a trimeric homodimer that forms from engineered peptides for the L19 antibody in scFv format fused to human TNF [1]. LIke bifikafusp alfa, Fibromun targets the TNF to the tumour microenvironment via L19 binding to the angiogenesis-associated isoform of fibronectin (specifically the extradomain B or EDB). Fibromun is being investigated as an immuno-oncology therapeutic. It is one of a growing number of so-called 'immunocytokines' entering clinical development.

References
1. Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, Kosmehl H, Biro A, Siri A, Orecchia P et al.. (2003) Selective targeted delivery of TNFalpha to tumor blood vessels. Blood, 102 (13): 4384-92. [PMID:12933583]
2. Danielli R, Patuzzo R, Di Giacomo AM, Gallino G, Maurichi A, Di Florio A, Cutaia O, Lazzeri A, Fazio C, Miracco C et al.. (2015) Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Cancer Immunol Immunother, 64 (8): 999-1009. [PMID:25971540]
3. List T, Neri D. (2013) Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin Pharmacol, 5: 29-45. [PMID:23990735]
4. Viti F, Tarli L, Giovannoni L, Zardi L, Neri D. (1999) Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res, 59 (2): 347-52. [PMID:9927045]

References

1. Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, Kosmehl H, Biro A, Siri A, Orecchia P et al.. (2003)
Selective targeted delivery of TNFalpha to tumor blood vessels.
Blood, 102 (13): 4384-92. [PMID:12933583]

2. Danielli R, Patuzzo R, Di Giacomo AM, Gallino G, Maurichi A, Di Florio A, Cutaia O, Lazzeri A, Fazio C, Miracco C et al.. (2015)
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study.
Cancer Immunol Immunother, 64 (8): 999-1009. [PMID:25971540]

3. List T, Neri D. (2013)
Immunocytokines: a review of molecules in clinical development for cancer therapy.
Clin Pharmacol, 5: 29-45. [PMID:23990735]

4. Viti F, Tarli L, Giovannoni L, Zardi L, Neri D. (1999)
Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis.
Cancer Res, 59 (2): 347-52. [PMID:9927045]